A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma

Cancer Immunology, Immunotherapy

Volumn 61, Issue 6, 2012, Pages 783-788

  Whiteside, Theresa L ^a   Butterfield, Lisa H ^a   Naylor, Paul H ^b   Egan, James E ^b   Hadden, John W ^b   Baltzer, Lorraine ^b   Wolf, Gregory T ^c   Berinstein, Neil L ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b IRX Therapeutics Inc   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cancer; Cytokines; HNSCC; Lymphocytes; Neoadjuvant IRX 2

Indexed keywords

CD3 ANTIGEN; CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYCLOPHOSPHAMIDE; IMMUNOMODULATING AGENT; INDOMETACIN; INTERLEUKIN 2; IRX 2; UNCLASSIFIED DRUG; ZINC;

ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; EFFECTOR CELL; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LYMPHOCYTE COUNT; MEMORY T LYMPHOCYTE; MULTICENTER STUDY; NATURAL KILLER T CELL; PERIPHERAL LYMPHOCYTE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

CARCINOMA, SQUAMOUS CELL; CYTOKINES; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; NEOADJUVANT THERAPY; T-LYMPHOCYTE SUBSETS;

EID: 84862313230     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1136-x     Document Type: Article

References (26)

1. Whiteside TL (2005) Immunobiology of head and neck cancer. Cancer Metastasis Rev 24:95-105
2. Specenier P, Vermorken JB (2011) Cetuximab in the treatment of squmaous cell carcinoma of the head and neck. Exp Rev Anti-cancer Ther 11:511-524
3. Janke M, Peeters B, Zhao H, deLeeuw O, Moorman R, Arnold A, Ziouta Y, Fournier P, Schirrmacher V (2008) Activation of human T cells by a tumor vaccine infected with recombinant newcastle disease virus producing IL-2. Int J Oncol 33:823-832
4. Ferris RL, Whiteside TL, Ferrone S (2006) Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res 12:3890-3895 (Pubitemid 44078071)
5. Young RM (2006) Protective mechanisms of head and neck squamous cell carcinomas from immune assult. Head Neck 28:462-470
6. Hadden JW (1995) The immunology of head and neck cancer: prospects for immunotherapy. Clin Immunother 3:362-385
7. Whiteside TL, Letessier E, Hirabayashi H, Vitolo D, Bryant J, Barnes L, Snyderman C, Johnson JT, Myers E, Herberman RB et al (1993) Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res 53:5654-5662 (Pubitemid 23360267)
8. Cortesina G, De Stefani A, Giovarelli M, Barioglio MG, Cavallo GP, Jemma C, Forni G (1988) Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically. Cancer 62:2482-2485 (Pubitemid 19006426)
9. Cortesina G, De Stefani A, Galeazzi E, Cavallo GP, Badellino F, Margarino G, Jemma C, Forni G (1994) Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin-2 injected perilymphatically. Br J Cancer 69:572-576 (Pubitemid 24076482)
10. De Stefani A, Valente G, Forni G, Lerda W, Ragona R, Cortesina G (1996) Treatment of oral cavity and oropharynx squamous cell carcinoma with perilymphatic interleukin-2: Clinical and pathologic correlations. J Immunother 19:125-133 (Pubitemid 26139070)
11. Hadden JW, Endicott J, Baekey P, Skipper P, Hadden EM (1994) Interleukins and contrasuppression induce immune regression of head and neck cancer. Arch Otolaryngol Head Neck Surg 120:395-403 (Pubitemid 24129004)
12. Meneses A, Verastegui E, Barrera JL, Zinser J, de la Garza J, Hadden JW (1998) Histologic findings in subjects with head and neck squamous cell carcinoma receiving perilymphatic natural cytokine mixture prior to surgery. Arch Pathol Lab Med 122:447-454 (Pubitemid 28237539)
13. Freeman SM, Franco JL, Kenady DE, Baltzer L, Roth Z, Brandwein HJ, Hadden JW (2011) A Phase I safety study of an IRX-2 regimen in subjects with squamous cell carcinoma of the head and neck. Am J Clin Oncol 34:173-178
14. Wolf GT, Fee WE, Dolan RW, Moyer JS, Kaplan MJ, Spring PM, Suen J, Kenady DE, Newman JG, Carroll WR et al (2011) Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer. Head Neck. doi:10.1002/hed.21660
15. Berlinger NT (1984) Deficient immunity in head and neck cancer due to excessive monocyte production of prostaglandins. Laryngoscope 94:1407-1411
16. Hadden J (1995) The treatment of zinc deficiency as an immunotherapy. Int J Immunopharmac 17:697
17. highFoxp3+ T cells in the peripheral circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 13:6301-6311
18. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL (2004) Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 10:3755-3762 (Pubitemid 38697609)
19. Pretscher D, Distel LV, Grabenbauer GG, Wittlinger M, Buettner M, Niedobitek G (2009) Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma. BMC Cancer 9:292-301
20. 264-272 peptide in the circulations of patients with head and neck cancer. Cancer Res 62:3521-3529
21. Kim J-W, Ferris RL, Whiteside TL (2005) Chemokine receptor 7 (CCR7) expression and protection of circulating CD8+ T lymphocytes from apoptosis. Clin Cancer Res 11:7901-7910 (Pubitemid 41611637)
22. highFOXP3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2. J Immunother 33:425-434
23. Bergmann C, Strauss L, Wang Y, Szczepanski MJ, Lang S, Johnson JT, Whiteside TL (2008) T regulatory type 1 cells (Tr1) in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 14:3706-3715
24. Bergmann C, Strauss L, Zeidler R, Lang S, Whiteside TL (2007) Expansion of human T regulatory type 1 cells in the microenvironment of COX-2 overexpressing head and neck squamous cell carcinoma. Cancer Res 67:8865-8873 (Pubitemid 47437463)
25. Czystowska M, Strauss L, Bergmann C, Szajnik M, Rabinowich H, Whiteside TL (2010) Reciprocal granzyme/perforin-mediated death of human regulatory and responder T cells is regulated by interleukin-2 (IL-2). J Mol Med 88:577-588
26. Berinstein NL, Wolf GT, Naylor PH, Baltzer L, Egan JE, Brandwein HJ, Whiteside TL, Goldstein L, El-Naggar A, Badoual C, Fridman W-H, White JM, Hadden JW (2011) Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen. Cancer Immunol Immunother (in press)